1. Home /
    2. Altai Protocol Library /
  2. New Indication: Docetaxel as a Radiosensitizer in Patients with Head and Neck Cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Indication: Docetaxel as a Radiosensitizer in Patients with Head and Neck Cancer

New Indication: Docetaxel as a Radiosensitizer in Patients with Head and Neck Cancer
Study:
  • Phase II/III, randomized, open-label study
  • Cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC)
  • Docetaxel-RT (n=180) vs. RT (n=176)
Efficacy:
  • 2-year DFS: 42% vs. 30.3%, HR: 0.67, p=0.002
  • Median locoregional failure-free survival: 12.4 vs. 5.9 mos, HR: 0.66, p=0.002
  • mOS: 25.5 vs. 15.3 mos, HR: 0.74, p=0.035
Safety:
  • Grade≥3 AEs: Odynphagia (52.5% vs. 33.5%), mucositis (49.7% vs 22.2%), dysphagia (49.7% vs. 33%)

J Clin Oncol 2023: 27 JAN.

Patil V.M et al. ¨ Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation¨

http://doi.org/10.1200/JCO.22.00980

Reviewed by Elvin CHALABİYEV, MD on FEB 24, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More